Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory Roundup: Device Ban Supported; Obesity Device Panel; Eyelid Weights

This article was originally published in The Gray Sheet

Executive Summary

FDA neuro panel supports FDA’s proposed ban of electrical stimulation devices used for “aversive conditioning.” The agency has officially scheduled an advisory panel meeting to consider EnteroMedics’s PMA for the implantable Maestro Rechargeable System as a weight-loss tool in obese patients. More regulatory news.

You may also be interested in...



FDA’s Upcoming Drug/Diagnostic Co-Development Guidance Could Quickly Become Outdated

Tests that look for many markers at a time “may completely change” the paradigm for companion diagnostics, CDRH’s Elizabeth Mansfield says.

China Biotech Podcast: BIOSECURE Updates, Genmab/Profound Deal

In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel